Thiogenesis Therapeutics Makes Debut on OTCQX Best Market
San Diego, CA – February 12, 2025 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”), a clinical-stage biotechnology company specializing in the development of disulfides that stimulate the production of essential intracellular antioxidants and other therapeutic compounds, recently announced its common shares have commenced trading on the OTCQX Best Market. This marks a significant milestone for Thiogenesis as it gains access to a broader investor base in the United States.
What is the OTCQX Best Market?
The OTCQX Best Market is the highest-level market of OTC Markets Group Inc., which is an international financial marketplace for trading 12,000 U.S. and global securities. Companies that meet specific financial, operational, and transparency requirements are eligible for this market. The OTCQX Best Market provides investors with the highest level of information and improved liquidity.
Impact on Thiogenesis
Thiogenesis’ inclusion on the OTCQX Best Market offers several benefits for the company. First, it will increase its visibility and accessibility to a larger pool of potential investors, including U.S. institutional investors. This can lead to increased liquidity and potentially higher trading volumes. Additionally, the OTCQX Best Market’s enhanced reporting requirements will provide investors with more transparent financial information, further bolstering confidence in the company.
Impact on Individual Investors
For individual investors, Thiogenesis’ listing on the OTCQX Best Market signifies a potential investment opportunity in a promising clinical-stage biotechnology company. Thiogenesis’ technology focuses on creating disulfides, which are essential for the production of intracellular antioxidants and other therapeutic compounds. This could lead to significant advancements in various therapeutic areas, including neurodegenerative diseases, cancer, and inflammatory conditions.
Impact on the World
Thiogenesis’ entry into the OTCQX Best Market is not only a win for the company and its investors but also for the scientific and medical community. The advancements Thiogenesis is making in the field of disulfide technology could lead to the development of new, effective treatments for various diseases. As a clinical-stage biotechnology company, Thiogenesis’ success could pave the way for other innovative biotech companies to follow suit, ultimately driving progress in the healthcare sector.
Conclusion
Thiogenesis Therapeutics’ debut on the OTCQX Best Market is an exciting development for the company and the biotech industry as a whole. This achievement provides Thiogenesis with greater visibility, accessibility to a larger investor base, and enhanced reporting requirements, all of which can lead to increased liquidity and investor confidence. For individual investors, this marks a potential investment opportunity in a promising clinical-stage biotechnology company with significant growth potential. Ultimately, Thiogenesis’ advancements in disulfide technology could lead to the development of new, effective treatments for various diseases, benefiting the global scientific and medical community.
- Thiogenesis Therapeutics commenced trading on the OTCQX Best Market under the ticker symbol TTIPF
- The OTCQX Best Market is the highest-level market of OTC Markets Group Inc., with enhanced reporting requirements and increased investor visibility
- Thiogenesis’ listing on the OTCQX Best Market offers increased visibility, accessibility to a larger investor base, and enhanced reporting requirements
- Individual investors may view Thiogenesis as a promising investment opportunity due to its focus on creating disulfides for the production of intracellular antioxidants and therapeutic compounds
- Thiogenesis’ success in the field of disulfide technology could pave the way for other innovative biotech companies and drive progress in the healthcare sector
